...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Japanese Journal of Ophthalmology >Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema.
【24h】

Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema.

机译：玻璃体内曲安奈德对黄斑水肿的疗效和保留时间。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To evaluate the retention of intravitreal triamcinolone acetonide (TA) particles and the efficacy of TA therapy for patients with cystoid macular edema in branch retinal vein occlusion (BRVO) or diabetic macular edema (DME). We monitored the TA particles until absorption from the vitreous cavity was complete. The correlation between the intravitreal retention time of TA and its efficacy was evaluated based on central macular thickness (CMT). RESULTS: The intravitreal TA retention time was a mean 141.8 +/- 139.6 days in BRVO patients and 114.5 +/- 59.6 days in DME patients. Patient age and retention time were negatively correlated (r = -0.46; P = 0.013). At 6 months posttreatment the mean CMT decreased from 544.1 +/- 143.7 to 322.4 +/- 131.9 mum in BRVO patients and from 454.5 +/- 119.0 to 371.2 +/- 209.4 mum in DME patients. Retention time and CMT reduction were positively correlated in BRVO patient (r = 0.56, P = 0.02) but not in DME patients (P = 0.06). CONCLUSIONS: Intravitreal TA reduced the CMT in BRVO and DME patients over 6 months. The retention time was longer in younger individuals. The efficacy of the therapy depended on the intravitreal TA retention time observed clinically in BRVO patients. Biomicroscopic examination of intravitreal TA is useful for evaluation of its efficacy.
机译：目的：评估玻璃体内曲安奈德（TA）颗粒的保留以及TA治疗对于视网膜分支支静脉阻塞（BRVO）或糖尿病性黄斑水肿（DME）的囊样性黄斑水肿患者的疗效。我们监测了TA颗粒，直到从玻璃体腔吸收完成为止。 TA的玻璃体内保留时间与其功效之间的相关性是根据中央黄斑厚度（CMT）进行评估的。结果：BRVO患者的玻璃体内TA保留时间平均为141.8 +/- 139.6天，而DME患者为114.5 +/- 59.6天。患者年龄和保留时间呈负相关（r = -0.46; P = 0.013）。治疗后6个月，BRVO患者的平均CMT从544.1 +/- 143.7降低到322.4 +/- 131.9，DME患者从454.5 +/- 119.0降低到371.2 +/- 209.4。 BRVO患者的保留时间和CMT降低呈正相关（r = 0.56，P = 0.02），而DME患者则没有（P = 0.06）。结论：玻璃体内TA降低了BRVO和DME患者6个月的CMT。年轻人的保留时间更长。该疗法的疗效取决于在BRVO患者中临床观察到的玻璃体内TA保留时间。玻璃体内TA的生物显微镜检查可用于评估其功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号